Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective Article

publication date

  • January 19, 2023

webpage

published in

keywords

  • Markov model
  • anticholinergic
  • beta 3-adrenoceptor agonist
  • cost-effectiveness
  • onabotulinumtoxinA
  • overactive bladder
  • quality-adjusted life-year
  • rechargeable sacral nerve stimulation